Clinical significance and correlation of FHIT methylation in serum of prostate cancer
LUO Rong -li，ZHANG Chun-ting，XU Min.,LI Chao,WANG Ya-xuan
Abstract:
Objective To detect the methylation status of fragile histidine triad (FHIT) gene in the serum of patients with prostate cancer, and to explore the relationship between FHIT methylation and clinical pathology, 5-year biochemical recurrence and clinical progression of prostate cancer. Methods The MSP method was used to detect FHIT gene methylation expression in the serum of 78 patients with prostate cancer and 45 patients with benign prostate hyperplasia. To analyze the relationship between FHIT methylation rate and clinical pathology of patients with prostate cancer, as well as the relationship between 5-year biochemical recurrence and 5-year clinical progression of prostate cancer in Kaplan Meier survival analysis. Results The methylation rate of FHIT gene in the serum of prostate cancer patients was 48.72%, the methylation rate of FHIT gene in the serum of patients with benign prostatic hyperplasia was 4.44%, and there was a significant difference between the two (P<0.05). FHIT methylation is associated with age, preoperative PSA, TNM staging, and Gleason grading in prostate cancer patients; The FHIT methylation rates in Gleason grade ≤ 7 and Gleason grade 8-10 of prostate cancer were 59.18% and 31.03%, respectively. The FHIT methylation rates in stages I-II and III-IV were 37.50% and 66.67%, respectively, with significant differences (P<0.05). FHIT methylation was higher in patients with 5-year biochemical recurrence and clinical progression of prostate cancer than in no biochemical recurrence and no clinical progression patients (P<0.05). Conclusion FHIT methylation is related to the clinical pathology of prostate cancer, and detecting FHIT methylation status can help evaluate the clinical prognosis of prostate cancer patients.
